Perspective Therapeutics, Inc. (CATX)

The past six months have seen significant movements in Perspective Therapeutics' stock. As of February 2, 2026, the stock was trading at $5.06, marking a 33.51% increase since the beginning of that trading day and a 53.33% increase from its price on February 3, 2025. However, as of February 24, 2025, the stock had plummeted to a 52-week low of $2.6, reflecting an 82.4% decline over the preceding six months. In February 2026, the company announced the pricing of a $175 million underwritten offering of common stock and pre-funded warrants. In October 2025, Perspective Therapeutics announced positive interim data from its lead cancer therapy trial, [212Pb]VMT-α-NET, which was considered a significant de-risking event, but CATX declined by 28.95% on the day this news was published. Lucid Capital Markets increased its price target for Perspective Therapeutics to $20 from $15, while RBC Capital adjusted its price target to $16 from $25. There has been insider buying activity in the past three months, with insiders purchasing $42,276.00 in company stock and no sales.

Direct information regarding demand seasonality for Perspective Therapeutics, Inc.'s products and services is not readily available. The demand for its products is primarily driven by medical necessity, disease prevalence, and clinical trial progress rather than typical consumer seasonal patterns. Significant demand seasonality is unlikely to be a major factor impacting the company's operations or revenue.

Perspective Therapeutics, Inc. (CATX) is a radiopharmaceutical development company focused on creating advanced treatment applications for various cancers, operating within the Healthcare sector, specifically in the Medical Devices and Instruments industry. The company utilizes proprietary technology involving the alpha-emitting isotope Lead-212 (212Pb) to deliver potent radiation directly to cancer cells through specialized targeting peptides. This theranostic approach includes developing imaging diagnostics with the same targeting peptides to personalize treatment and optimize patient outcomes. The company's major product candidates include VMT-α-NET, VMT01, PSV359, PSV4XX, and a 212Pb generator.

Perspective Therapeutics, Inc. primarily develops and commercializes its therapies in the United States. The company has a vertically integrated manufacturing network with facilities in New Jersey and Iowa, and plans for expansion into Chicago, Houston, and Los Angeles to ensure a reliable supply of its products.

Perspective Therapeutics has experienced a mixed brand reputation over the past year. The company has received a consensus "Buy" rating from analysts, with an average price target of $11.17. The company's stock performance also exceeded the US Biotechs industry and the broader US Market over the past year. Positive interim clinical trial data for VMT-α-NET presented at conferences have been highlighted as significant de-risking events and promising efficacy signals. However, the sharp decline in stock price in November 2024, following an interim data update for VMT-α-NET, indicates a period of market disappointment regarding the efficacy side of the data.

Institutional investors hold a significant portion of Perspective Therapeutics' stock, ranging from approximately 0.03% to 54.66%. Major institutional shareholders include Fmr Llc, BlackRock, Inc., Vanguard Group Inc, Avidity Partners Management LP, Morgan Stanley, Millennium Management Llc, UBS Group AG, and JPMorgan Chase & Co. Individual investors hold approximately 73.14% of the company's stock. Insider ownership stands at about 2.54% to 3.72%.